has been added to the
Pharmaceutical Benefits Scheme,
for the the management of
advanced Parkinson’s disease in
adults with severe, disabling motor
movements) not adequately
controlled by oral therapy.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 05 May 11 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 May 11
THE Australian Consensus Framework for Ethical Collaboration in the Healthcare Sector was launched in Tokyo last week, with 50 signatories including Pharmacy Guild of Australia, SHPA, ASMI, CMA, CHF, Medicines Australia and NPS Medicinewise.